Legal & General Group Plc Buys 2,222 Shares of ICU Medical, Inc. $ICUI

Legal & General Group Plc boosted its stake in ICU Medical, Inc. (NASDAQ:ICUI) by 3.4% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 67,773 shares of the medical instruments supplier’s stock after buying an additional 2,222 shares during the period. Legal & General Group Plc’s holdings in ICU Medical were worth $8,956,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. William Blair Investment Management LLC bought a new position in shares of ICU Medical during the second quarter valued at $27,928,000. The Manufacturers Life Insurance Company grew its holdings in shares of ICU Medical by 992.1% in the 1st quarter. The Manufacturers Life Insurance Company now owns 130,762 shares of the medical instruments supplier’s stock worth $18,158,000 after purchasing an additional 118,789 shares during the last quarter. MetLife Investment Management LLC increased its position in shares of ICU Medical by 850.4% during the 1st quarter. MetLife Investment Management LLC now owns 123,041 shares of the medical instruments supplier’s stock worth $17,085,000 after purchasing an additional 110,095 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of ICU Medical by 18.5% during the 1st quarter. Ameriprise Financial Inc. now owns 693,711 shares of the medical instruments supplier’s stock worth $96,326,000 after purchasing an additional 108,493 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in ICU Medical by 80.1% during the 1st quarter. Invesco Ltd. now owns 203,827 shares of the medical instruments supplier’s stock valued at $28,303,000 after purchasing an additional 90,674 shares during the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical Stock Down 1.5%

NASDAQ:ICUI opened at $146.22 on Tuesday. The company has a market cap of $3.61 billion, a price-to-earnings ratio of -96.20 and a beta of 0.83. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.17 and a current ratio of 2.44. The stock’s fifty day moving average price is $127.80 and its two-hundred day moving average price is $128.57. ICU Medical, Inc. has a 52-week low of $107.00 and a 52-week high of $175.51.

ICU Medical (NASDAQ:ICUI) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.43 by $0.60. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The company had revenue of $533.30 million during the quarter, compared to the consensus estimate of $511.46 million. During the same quarter in the previous year, the company posted $1.59 earnings per share. The firm’s quarterly revenue was down 8.9% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. On average, analysts anticipate that ICU Medical, Inc. will post 4.11 EPS for the current year.

Insider Activity

In other news, Director Elisha W. Finney sold 1,285 shares of ICU Medical stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $140.42, for a total transaction of $180,439.70. Following the completion of the sale, the director owned 3,995 shares in the company, valued at $560,977.90. The trade was a 24.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Virginia Ruth Sanzone sold 930 shares of the stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $142.34, for a total transaction of $132,376.20. Following the completion of the transaction, the vice president owned 5,456 shares in the company, valued at $776,607.04. This represents a 14.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

ICUI has been the topic of several research analyst reports. Wall Street Zen cut shares of ICU Medical from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. KeyCorp increased their price target on ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ICU Medical in a report on Wednesday, October 8th. Piper Sandler lifted their price objective on ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Finally, Raymond James Financial decreased their target price on ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $181.75.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.